Cargando…
Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
Background: Fingolimod is approved in relapsing-remitting multiple sclerosis (RRMS) with the recommended dose of 0.5 mg daily. To tackle possible adverse events, some clinicians may reduce the dose of fingolimod, mainly in the alternate-day form. We systematically reviewed the literature for efficac...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Tehran University of Medical Sciences
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460927/ https://www.ncbi.nlm.nih.gov/pubmed/38011360 http://dx.doi.org/10.18502/cjn.v22i2.13339 |